PubMed

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.

Hadjimichael O, Vollmer T, Oleen-Burkey M; North American Research Committee on Multiple Sclerosis.

Health Qual Life Outcomes. 2008 Nov 14;6:100.PMID: 19014588 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry.

Lo AC, Hadjimichael O, Vollmer TL.

Mult Scler. 2005 Feb;11(1):33-40.PMID: 15732264 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.

J Manag Care Pharm. 2007 Apr;13(3):245-61.PMID: 17407391 [PubMed - indexed for MEDLINE]Related articlesFree article

Persistent pain and uncomfortable sensations in persons with multiple sclerosis.

Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T.

Pain. 2007 Jan;127(1-2):35-41. Epub 2006 Sep 1.PMID: 16949751 [PubMed - indexed for MEDLINE]Related articles

Validation of the NARCOMS registry: fatigue assessment.

Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T.

Mult Scler. 2005 Oct;11(5):583-4.PMID: 16193897 [PubMed - indexed for MEDLINE]Related articles

Prevalence and treatment of spasticity reported by multiple sclerosis patients.

Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL.

Mult Scler. 2004 Oct;10(5):589-95.PMID: 15471378 [PubMed - indexed for MEDLINE]Related articles

Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters.

Flachenecker P, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV.

Mult Scler. 2002 Dec;8(6):523-6.PMID: 12474995 [PubMed - indexed for MEDLINE]Related articles

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.PMID: 19739877 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.

Simone IL, Ceccarelli A, Tortorella C, Bellacosa A, Pellegrini F, Plasmati I, De Caro MF, Lopez M, Girolamo F, Livrea P.

Health Qual Life Outcomes. 2006 Dec 12;4:96.PMID: 17163989 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.

Ziemssen T, Hoffman J, Apfel R, Kern S.

Health Qual Life Outcomes. 2008 Sep 5;6:67.PMID: 18775064 [PubMed - indexed for MEDLINE]Related articlesFree article

Disparities in the management of multiple sclerosis-related bladder symptoms.

Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D.

Neurology. 2007 Jun 5;68(23):1971-8.PMID: 17548546 [PubMed - indexed for MEDLINE]Related articles

Therapy with glatiramer acetate for multiple sclerosis.

Munari L, Lovati R, Boiko A.

Cochrane Database Syst Rev. 2004;(1):CD004678. Review.PMID: 14974077 [PubMed - indexed for MEDLINE]Related articles

What drives quality of life in multiple sclerosis?

Hemmett L, Holmes J, Barnes M, Russell N.

QJM. 2004 Oct;97(10):671-6.PMID: 15367738 [PubMed - indexed for MEDLINE]Related articlesFree article

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.

Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C; QUASIMS Study Group.

J Neurol. 2007 Jan;254(1):67-77. Epub 2007 Feb 1.PMID: 17273808 [PubMed - indexed for MEDLINE]Related articles

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, Bell RB, Yeung M, Murphy WF, Stoian CA, Billesberger K, Tillotson L, Peters S, McGowan D.

J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1045-7.PMID: 15201369 [PubMed - indexed for MEDLINE]Related articlesFree article

Cognitive fatigue in multiple sclerosis: findings from a two-wave screening project.

Barak Y, Achiron A.

J Neurol Sci. 2006 Jun 15;245(1-2):73-6. Epub 2006 Apr 19.PMID: 16626750 [PubMed - indexed for MEDLINE]Related articles

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.PMID: 15623672 [PubMed - indexed for MEDLINE]Related articles

Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?

Téllez N, Río J, Tintoré M, Nos C, Galán I, Montalban X.

Mult Scler. 2005 Apr;11(2):198-202.PMID: 15794395 [PubMed - indexed for MEDLINE]Related articles

Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.

Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V.

Eur Neurol. 2008;59(3-4):136-42. Epub 2007 Nov 30.PMID: 18057900 [PubMed - indexed for MEDLINE]Related articles

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Harung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2009 Nov;8(11):981. PMID: 19729344 [PubMed - indexed for MEDLINE]Related articles